<DOC>
	<DOC>NCT00219102</DOC>
	<brief_summary>To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of valsartan and hydrochlorothiazide</brief_summary>
	<brief_title>A Clinical Study to Evaluate Safety &amp; Efficacy of the Combination of Aliskiren, Valsartan &amp; Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion Criteria Patients with essential hypertension Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus. Patients who are eligible and able to participate in the study Exclusion Criteria Severe hypertension Uncontrolled diabetes type I and II History or evidence of a secondary form of hypertension History of Hypertensive encephalopathy or cerebrovascular accident. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Hypertension,</keyword>
	<keyword>diabetes,</keyword>
	<keyword>aliskiren,</keyword>
	<keyword>blood pressure,</keyword>
	<keyword>valsartan,</keyword>
	<keyword>hydrochlorothiazide</keyword>
</DOC>